Nektar Therapeutics earnings up 173% in Q1

• Nektar Therapeutics (NASDAQ:NKTR +15.1%) Q1 results: Revenues: $108.8M (+449.5%); COGS: $8.4M (+6.3%); R&D Expense: $47M (+22.7%); SG&A: $10.3M (+4.0%); Operating Income: $43M (+218.1%); Net Income: $33.8M (+173.2%); EPS: $0.25 (+167.6%); Quick Assets: $300.8M (+26.5%).
• No guidance given.